|
🦁
|
MRI T2 lesion burden in multiple sclerosis
12 auth.
David K. B. Li,
Ulrike Held,
J. Petkau,
M. Daumer,
F. Barkhof,
F. Fazekas,
...
Joseph A. Frank,
L. Kappos,
David H. Miller,
J. Simon,
J. Wolinsky,
M. Filippi
|
7 |
2006 |
7
🦁
|
|
🐜
|
Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials
13 auth.
F. Barkhof,
Ulrike Held,
Jack H. Simon,
M. Daumer,
F. Fazekas,
M. Filippi,
Joseph A. Frank,
L. Kappos,
David K. B. Li,
S. Menzler,
...
Dh Miller,
J. Petkau,
J. Wolinsky
|
5 |
2005 |
5
🐜
|
|
🐜
|
Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension
13 auth.
Ludwig Kappos,
A. Traboulsee,
David K. B. Li,
Amit Bar-Or,
F. Barkhof,
X. Montalbán,
D. Leppert,
Anna Baldinotti,
H. Schneble,
H. Koendgen,
...
A. Sauter,
Qing Wang,
S. L. Hauser
|
2 |
2023 |
2
🐜
|
|
🐜
|
Phase 2 BOLD Extension Study Efficacy Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P07.110)
14 auth.
Olaf Stuve,
H-P. Hartung,
Mark S. Freedman,
David K. B. Li,
B. Hemmer,
L. Kappos,
Peter Rieckmann,
X. Montalban,
T. Ziemssen,
Lixin Zhang-Auberson,
...
Brian Hunter,
E. Rochotte,
Erik Wallstrom,
Krzysztof W. Selmaj
|
0 |
2013 |
0
🐜
|
